Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. has announced amendments to its Articles of Association following the placement of 19,000,000 new H Shares, which resulted in an increase in the company’s registered capital. The amendments, approved by the Board on August 22, 2025, reflect changes in the shareholding structure and authorize the management to carry out necessary procedures in compliance with domestic and international requirements. This strategic move is expected to enhance RemeGen’s operational capabilities and strengthen its market position.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company is focused on the development and commercialization of biologic drugs, with a market focus on innovative therapies in the fields of oncology, autoimmune, and ophthalmic diseases.
Average Trading Volume: 11,836,738
Technical Sentiment Signal: Buy
Current Market Cap: HK$47.71B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.